Navigation Links
Blizzard, McCarthy & Nabers Launches

Informs Public of Serious Risks Associated with Use of Reglan and Metoclopramide: Provides Solutions for Legal Recourse

HOUSTON, March 9 /PRNewswire-USNewswire/ -- Blizzard, McCarthy & Nabers, one of the nation's leading pharmaceutical litigation firms is proud to announce the launch of, an educational website aimed at informing consumers of the risks associated with the use of the drug Reglan, and its generic form, metoclopramide.  As a resource for the millions of Americans who use this drug, is regularly updated with the latest news and medical information surrounding the medication and its causal link to debilitative movement disorders.

Long-term use of Reglan and generic forms of metoclopramide has been linked to Tardive Dyskinesia, a serious involuntary and repetitive movement disorder that is often irreversible. A recent study cited by the FDA, reports the prevalence of Tardive Dyskinesia at 20 percent among patients treated with Reglan for at least 12 weeks. In February 2009, the FDA issued a Black Box warning against continued use of Reglan to treat gastrointestinal disorders. is meant to provide consumers with the critical information denied to them by the pharmaceutical manufacturers marketing these drugs.  For those consumers who have already been disabled by these products, provides an avenue to seek legal redress.  Corporations that operate with an eye on the bottom line rather than the safety of their consumers must be held accountable for their actions.  For more information, visit

"As attorneys, we've seen first hand the damage that can be done by these powerful and dangerous drugs," said Scott Nabers, partner at Blizzard, McCarthy & Nabers.  "Consumers were misinformed about the risks associated with this product and many have been permanently disabled.  It is our hope that this website will provide consumers with critical information so that future patients can avoid these troubling side effects."

In January, the firm launched to provide information and avenues to legal recourse for consumers poisoned by zinc in denture cream.

Blizzard, McCarthy & Nabers, LLP, one of the nation's leading pharmaceutical litigation firms, represents thousands of clients harmed by dangerous drugs and medical devices and has taken on some of the world's largest corporations, including Bristol-Myers, GlaxoSmithKline, Merck, Pfizer and Dow Chemical. 

SOURCE Blizzard, McCarthy & Nabers, LLP

Back to top



SOURCE Blizzard, McCarthy & Nabers, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. International Growth Continues: Rhythmlink International, LLC Receives CE Marking & ISO 13485 Certification
2. Neurocrine Biosciences to Present at the 30th Annual Cowen & Co. Health Care Conference
3. P&M Corporate Finance and Robin Young Announce 2010 Spine Technology Summit
4. 2nd Annual Orthopedic Design & Technology Forum Returns April 28 to the FedEx Institute of Technology, University of Memphis
5. TransMedics, Inc. Secures $36 Million Round of Financing Lead by Foundation Capital and Kleiner Perkins Caufield & Byers
6. UBM Announces Plans for Japan Pharma & Bio Events
7. Frost & Sullivan Recognizes Timoptic(R) (timolol maleate) as Best Brand Name Beta Blocker for Glaucoma: Timoptic Brand is Highest Rated in Survey of Ophthalmologists
8. Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review
9. China Biologic Products to Present at the Rodman & Renshaw Annual China Investment Conference
10. Johnson & Johnson to Participate in the 30th Annual Cowen and Company Health Care Conference
11. Aurora Womens Pavilion Center for Sexual Health & Wellness Receives Grant to Treat Vulvar Pain
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 Avery Biomedical Devices (ABD), ... to announce the appointment of Anders Jonzon , ... Dr. Jonzon is a ... Children,s Hospital, Uppsala University, Uppsala and Children,s Hospital, Karolinska, ... was a fellow at the Cardiovascular Institute (UCSF). His ...
(Date:11/24/2015)... DALLAS , Nov. 24, 2015  Ascendant Solutions, Inc. ... announced that its Board of Directors has declared a special ... The stock dividend is payable December 14, 2015, to shareholders ... in the form of additional shares of common stock. ... by the Board is a strong endorsement of our confidence ...
(Date:11/24/2015)... st  Scientific Assembly and Annual Meeting of the Radiological Society of ... Chicago on Nov-29 th through Dec-4 th ... Assembly and Annual Meeting of the Radiological Society of ... on Nov-29 th through Dec-4 th , in ... its revolutionary whole body CZT digital SPECT/CT solution at the upcoming ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... ... their Black Friday sale a week early, offering 40% off select bras and ... intimate apparel industry through both mobile fit technology and the latest fashion, quickly ...
(Date:11/24/2015)... N.J. (PRWEB) , ... November 25, 2015 , ... ... delivery technologies and development solutions for drugs, biologics, consumer health and global clinical ... will present at the upcoming Clinical Trial Supply East Asia Conference, to be ...
(Date:11/24/2015)... ... 24, 2015 , ... The hospitals and health systems on ... orthopedic care. They have received recognition for excellence from various reputable organizations in ... Becker's Hospital Review selected hospitals for inclusion based on national rankings and awards ...
(Date:11/24/2015)... UT (PRWEB) , ... November 24, 2015 , ... It ... Magazine. For a business, it is critical that the first impression be positive and ... they are not likely to buy anything or want to return. They will also ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy Corp. Congress ... the developer of renewable energy technologies capable of producing commercially useful amounts of ... that its WET™ and HHT™ Boiler System reactor core modules were presented to ...
Breaking Medicine News(10 mins):